59 related articles for article (PubMed ID: 17311534)
1. Tyrosine kinase mutations in human cancer.
Lengyel E; Sawada K; Salgia R
Curr Mol Med; 2007 Feb; 7(1):77-84. PubMed ID: 17311534
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases.
Hashimoto K; Rogozin IB; Panchenko AR
Hum Mutat; 2012 Nov; 33(11):1566-75. PubMed ID: 22753356
[TBL] [Abstract][Full Text] [Related]
3. Supercharging T cell therapy with cancer mutations.
Marchal I
Nat Biotechnol; 2024 Mar; 42(3):379. PubMed ID: 38491282
[No Abstract] [Full Text] [Related]
4. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin.
McDonell LM; Kernohan KD; Boycott KM; Sawyer SL
Hum Mol Genet; 2015 Oct; 24(R1):R60-6. PubMed ID: 26152202
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H; Kaplan B; Mertins P; Chen TH; Tanaka KE; Yun CH; Zhang X; Lee SH; Cho J; Ambrogio L; Liao R; Imielinski M; Banerji S; Berger AH; Lawrence MS; Zhang J; Pho NH; Walker SR; Winckler W; Getz G; Frank D; Hahn WC; Eck MJ; Mani DR; Jaffe JD; Carr SA; Wong KK; Meyerson M
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14476-81. PubMed ID: 22908275
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Computational Enzyme Modeling: From Mechanisms to Design and Drug Development.
Nam K; Shao Y; Major DT; Wolf-Watz M
ACS Omega; 2024 Feb; 9(7):7393-7412. PubMed ID: 38405524
[TBL] [Abstract][Full Text] [Related]
7. Molecular Dynamics and Machine Learning Give Insights on the Flexibility-Activity Relationships in Tyrosine Kinome.
Majumdar S; Di Palma F; Spyrakis F; Decherchi S; Cavalli A
J Chem Inf Model; 2023 Aug; 63(15):4814-4826. PubMed ID: 37462363
[TBL] [Abstract][Full Text] [Related]
8. Molecular Simulations of Conformational Transitions within the Insulin Receptor Kinase Reveal Consensus Features in a Multistep Activation Pathway.
Nam K; Tao Y; Ovchinnikov V
J Phys Chem B; 2023 Jul; 127(26):5789-5798. PubMed ID: 37363953
[TBL] [Abstract][Full Text] [Related]
9. Transient Ca
Honsho M; Mawatari S; Fujino T
Front Mol Biosci; 2022; 9():1008626. PubMed ID: 36406270
[TBL] [Abstract][Full Text] [Related]
10. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
Cakiroglu E; Senturk S
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916
[TBL] [Abstract][Full Text] [Related]
11. Curcumin: An age-old anti-inflammatory and anti-neoplastic agent.
Fadus MC; Lau C; Bikhchandani J; Lynch HT
J Tradit Complement Med; 2017 Jul; 7(3):339-346. PubMed ID: 28725630
[TBL] [Abstract][Full Text] [Related]
12. HUMAN KINASES DISPLAY MUTATIONAL HOTSPOTS AT COGNATE POSITIONS WITHIN CANCER.
Gallion J; Wilkins AD; Lichtarge O
Pac Symp Biocomput; 2017; 22():414-425. PubMed ID: 27896994
[TBL] [Abstract][Full Text] [Related]
13. Signals and Receptors.
Heldin CH; Lu B; Evans R; Gutkind JS
Cold Spring Harb Perspect Biol; 2016 Apr; 8(4):a005900. PubMed ID: 27037414
[TBL] [Abstract][Full Text] [Related]
14. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
Kanteti R; Dhanasingh I; El-Hashani E; Riehm JJ; Stricker T; Nagy S; Zaborin A; Zaborina O; Biron D; Alverdy JC; Im HK; Siddiqui S; Padilla PA; Salgia R
Cancer Biol Ther; 2016; 17(1):91-103. PubMed ID: 26574927
[TBL] [Abstract][Full Text] [Related]
15. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
Cecchi F; Rabe DC; Bottaro DP
Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
[TBL] [Abstract][Full Text] [Related]
16. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
17. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Sudo T; Tagawa Y; Nishimura R; Ishiko O; Kanai Y; Yaegashi N; Aburatani H; Shiozawa T; Konishi I
Sci Rep; 2011; 1():180. PubMed ID: 22355695
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
19. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
20. PKC and the control of localized signal dynamics.
Rosse C; Linch M; Kermorgant S; Cameron AJ; Boeckeler K; Parker PJ
Nat Rev Mol Cell Biol; 2010 Feb; 11(2):103-12. PubMed ID: 20094051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
